Melovem

Meloxicam, the active ingredient in Melovem, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for systemic use. It is employed to relieve pain and inflammation in chronic arthritic conditions and acute musculoskeletal pain.

GNH USA supplies Melovem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID that targets inflammatory pathways in musculoskeletal disorders. - Osteoarthritis: reduces joint pain and improves functional mobility. - Rheumatoid arthritis: diminishes synovial inflammation and slows disease‑related joint damage. - Ankylosing spondylitis: alleviates spinal stiffness and chronic back pain. - Acute pain: provides short‑term relief of moderate to severe pain associated with injury or surgery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain. - Headache or dizziness. - Peripheral edema. - Mild skin rash.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Cardiovascular events such as myocardial infarction or stroke. - Severe hepatic injury or elevated liver enzymes. - Acute renal failure or worsening of chronic kidney disease. - Life‑threatening skin reactions (e.g., Stevens‑Johnson syndrome).

Before initiating therapy, clinicians should evaluate individual risk factors and monitor relevant organ systems. - Gastrointestinal risk: assess history of ulcer disease or bleeding. - Cardiovascular risk: avoid in patients with recent myocardial infarction or uncontrolled hypertension. - Renal function: monitor serum creatinine in patients with pre‑existing kidney disease. - Hepatic function: check liver enzymes periodically. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Meloxicam can alter the pharmacodynamics of several co‑administered agents.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - ACE inhibitors or ARBs: potential for reduced renal function. - Lithium: elevated serum lithium levels. - Methotrexate: enhanced toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: possible reduction in antihypertensive effect. - Antihypertensives: may blunt blood‑pressure control. - SSRIs or SNRIs: heightened bleeding tendency. - Corticosteroids: increased risk of gastrointestinal ulceration. - Cyclosporine: potential for nephrotoxicity.